Key Team Members & Collaborators

Co-founders

Sam van Bohemen, Co-founder, CEO, CTO & Biomedical Engineering PhD Candidate

Dr David Cardoso, Co-founder, CBO

Strategic Advisors

Dr Philip Boughton, Biomedical Engineering, Head GSI-Lab

Dr David Lester, MedTech Commercialisation

Chris Baxter, Intellectual Property & Commercialisation Expert

Commercialisation & Healthcare Readiness

Paul Cohen, Clinical & Regulatory Affairs Expert

Dr Eugene Salole, Market Access & HTA Expert

Hayley Saddington, MedTech entrepreneurship & commercialisation

Clinical Support

Professor Craig Anderson, Neurologist & Director of Global Brain Health at The George Institute

Dr Candice Delcourt, Senior Research Fellow & Head of the Neurology Program at The George Institute

A/Prof Noel Young, Radiology

Cross-Disciplinary Innovation

Strategic Partnership

We have formed an exciting strategic partnership with The George Institute for Global Health, a leading, not-for-profit medical research institute focused on solving the world's biggest health challenges, including stroke. We are thrilled to work together as we seek to revolutionise stroke patient care and improve outcomes, especially in underserved communities.

A Wearable To Meet Urgent Need

Stroke is a critical medical condition that is anticipated to increase in prevalence with aging populations. COVID-19 has recently been linked to severe ischemic strokes. Technology that can provide objective real-time insights to assist with timely interventions are being sought after to limit brain injury and death.

The proprietary nuroflux™ wearable system will non-invasively monitor brain activity and blood flow alongside vital activity to assist specialists. The current gold-standard for objective brain blood flow in stroke patients is CT perfusion imaging. Repeated CT perfusion imaging is limited due to the ionizing radiation exposure risk for patients. Furthermore CT imaging does not provide continuous monitoring. In the time periods between CT scans (including during trearment) there is no way to quantitatively monitor brain activity and blood flow.

nuroflux™ is being developed to provide continuous, realtime monitoring of stroke treatment, to detect signs of new stroke events and to monitor stroke rehabilitation.

There is also scope for the nuroflux™ to be used in pre-hospital settings to help diagnose and monitor stroke patients.

The recurrence of stroke is a stark possibility for stroke patients in the short and long term. nuroflux™ is being designed to be self-administered for remote monitoring outside the clinic for at-risk patients.